Skip to main content
SpringerLink
Log in

Donepezil: a guide to its use in Alzheimer’s disease

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2006 Jan 25; (1): CD001190

    PubMed  Google Scholar 

  2. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006 Jan 25; (1): CD005593

    PubMed  Google Scholar 

  3. Aricept 5 and 10 mg film coated tablets: summary of product characteristics. Hatfield: Eisai Ltd, 2009 May

  4. Aricept Evess 5 and 10 mg orodispersible tablets: summary of product characteristics. Hatfield: Eisai Ltd, 2007 Sep

  5. Electronic Medicines Compendium. Reminyl (galantamine) tablets, oral solution and prolonged-release capsules: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2009 Jul 7]

  6. Electronic Medicines Compendium. Exelon (rivastigmine): capsules, oral solution and transdermal patch: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2009 Jul 7]

  7. Jacobson SA, Sabbagh MN. Donepezil: potential neuroprotective and disease-modifying effects. Expert Opin Drug Metab Toxicol 2008 Oct; 4(10): 1363–9

    Article  PubMed  CAS  Google Scholar 

  8. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7(6): 293–303

    PubMed  CAS  Google Scholar 

  9. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50(1): 136–45

    Article  PubMed  CAS  Google Scholar 

  10. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May 11; 158(9): 1021–31

    Article  PubMed  CAS  Google Scholar 

  11. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3): 237–44

    Article  PubMed  CAS  Google Scholar 

  12. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000 Nov-Dec; 11(6): 299–313

    Article  PubMed  CAS  Google Scholar 

  13. Johannsen P, Salmon E, Hampel H, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs 2006; 20(4): 311–25

    Article  PubMed  CAS  Google Scholar 

  14. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14; 57(3): 489–95

    Article  PubMed  CAS  Google Scholar 

  15. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14; 57(3): 481–8

    Article  PubMed  CAS  Google Scholar 

  16. Wimo A, Winblad B, Shah SN, et al. Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin 2004 Aug; 20(8): 1221–5

    Article  PubMed  CAS  Google Scholar 

  17. Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 16(1): 15–24

    Article  PubMed  CAS  Google Scholar 

  18. Boada-Rovira J, Brodaty H, Cras P, et al. Efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21(1): 45–53

    Article  Google Scholar 

  19. Hager K, Calabrese P, Frölich L, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 15(4): 189–98

    Article  PubMed  CAS  Google Scholar 

  20. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 Jan 21; 291(3): 317–24

    Article  PubMed  CAS  Google Scholar 

  21. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008 Feb; 5(1): 83–9

    Article  PubMed  CAS  Google Scholar 

  22. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39

    Article  PubMed  CAS  Google Scholar 

  23. Bentué-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003; 17(13): 947–63

    Article  PubMed  Google Scholar 

  24. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin. 2005 Aug; 21(8): 1317–27

    Article  PubMed  CAS  Google Scholar 

  25. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 2003; 20(10): 777–89

    Article  PubMed  CAS  Google Scholar 

  26. Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs 2009; 23(4): 293–307

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donepezil: a guide to its use in Alzheimer’s disease. Drugs Ther. Perspect 25, 5–8 (2009). https://doi.org/10.2165/0042310-200925090-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925090-00002

Search

Navigation